NY-PYRAMID-ANALYTICS
23.3.2022 13:02:12 CET | Business Wire | Press release
Despite accelerated digital transformation of businesses over the past two years, almost one-third of companies surveyed for a Data & Analytics and Data Platforms study have yet to fully embrace a data-driven approach to strategic decision-making. A new Business Impact Brief commissioned by Pyramid Analytics from 451 Research, part of S&P Global Market Intelligence, states that the emerging discipline of Decision Intelligence could help improve business performance by placing data-driven decision-making within the reach of more personnel within an organization. This means decisions can be made by individuals beyond those who are proficient or skilled in interpreting information and crunching it for insights.
Key Points:
- Almost one-third (32%) of companies have yet to fully embrace a data-driven approach to strategic decision-making, according to 451 Research’s Voice of the Enterprise: Data & Analytics, Data Platforms 2021 survey. That means a sizable number of organizations are missing out on the benefits of utilizing data as a decision-making tool.
- Not all DI platforms provide the same functionality or meet the same needs. Companies should choose Decision Intelligence platforms with rigorous data management and a wide array of analytical functions.
- Decision intelligence requires new software which includes AI and machine learning.
- AI puts the “intelligence” into Decision Intelligence, lowering the skills barrier by automating the complex steps required for a data-driven approach.
- Download the 451 Research report Decision Intelligence: A New Enabler for Data-Driven Decisions [Ungated].
- Click here to schedule a demo of the Pyramid Decision Intelligence Platform .
When an organization effectively uses data to make decisions, it can lead to increased sales, improved business agility, better customer service and engagement, and empowered internal decision-makers. Decision Intelligence: A New Enabler for Data-Driven Decisions is available exclusively from Pyramid Analytics.
Complete, Unified Decision Intelligence
Only the Pyramid Decision Intelligence Platform unifies Data Preparation, Business Analytics, and Data Science on a single, integrated platform. This eliminates the need to use multiple disparate tools and the associated license cost and management complexity. Lower Total Cost of Ownership (TCO), rapid rollout, quicker and direct access to all available data, and industry-leading user adoption means faster time to value. The Pyramid Decision Intelligence Platform can be deployed on-premises, into a private or public cloud, embedded into other apps or delivered through Managed Services Providers (MSP).
Pyramid’s Decision Intelligence strategy was described as evolutionary in a recent analyst report. Pyramid Analytics Plants Stake in Decision Intelligence Ground , authored by Krishna Roy, Senior Research Analyst on the Data, AI & Analytics team at 451 Research, examines Pyramid’s Decision Intelligence Platform in the context of the emerging decision intelligence market which experts see as the next evolution in analytics and business intelligence (ABI).
Quotes
Krishna Roy
, Senior Research Analyst for the Data, AI & Analytics team, 451 Research, part of S&P Global Market Intelligence:
“Decision intelligence is still in its infancy. But its potential to support digital transformation by increasing the levels of data-driven decision-making in an organization is significant. Increased sales, improved business agility, enhanced customer service and engagement, and more empowered and aligned internal decision-makers can all be achieved when data-driven decision-making is effectively implemented. Decision intelligence platforms are likely to play a key role in enabling organizations to realize these benefits.”
Chas Kielt , Vice President of Global Corporate Communications and Partner Marketing, Pyramid Analytic s: “Decision Intelligence is emerging technology that meets all traditional BI and Analytics needs, but delivers accessibility, performance, context, scalability and rich functionality that greatly surpasses legacy tools. Slapping a decision intelligence label on a limited data visualization point product doesn’t make it so. With this report, the 451 Research team is helping data scientists, data analysts, and data-minded business professionals understand the Decision Intelligence market landscape.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Learn more at Pyramid Analytics .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005316/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
